原生质体异种融合技术选育他克莫司高产菌株  

Screening of Tacrolimus High-Producing Strain by Protoplast Heterologous Fusion Technology

作　　者：严凌斌 张杨杰[1] 张祝兰 陈洲琴[2] 林仙菊 连云阳 YAN Lingbin;ZHANG Yangjie;ZHANG Zhulan;CHEN Zhouqin;LIN Xianju;LIAN Yunyang(School of Pharmacy,Fujian Medical University,Fuzhou 350122,China;Fujian Provincial Key Laboratory of Screening for Novel Mcrobial Products,Fujian Institute of Microbiology,Fuzhou 350007,China)

机构地区：[1]福建医科大学药学院,福建福州350122 [2]福建省微生物研究所福建省新药(微生物)筛选重点实验室,福建福州350007

出　　处：《化学与生物工程》2025年第4期28-31,共4页Chemistry & Bioengineering

基　　金：福建省属公益类研究所基本科研专项(2022R1005002,2020R1005009)。

摘　　要：以筑波链霉菌(Streptomyces tsukubaensis)FIM-17-244和吸水链霉菌(Streptomyces hygroscopicus)FIM-24-69为亲本菌株,通过原生质体异种融合技术筛选获得一株孢子量丰富的他克莫司(FK506)高产融合菌株FIM-22-86,其摇瓶发酵效价较亲本菌株FIM-17-244提高了15.5%;融合菌株FIM-22-86的遗传性状稳定,在1 t发酵罐中连续发酵3个批次,平均发酵效价达1771μg·mL^(-1),有望用于降低FK506工业化生产成本。Taking Streptomyces tsukubaensis FIM-17-244 and Streptomyces hygroscopicus FIM-24-69 as parent strains,we screened a Tacrolimus(FK506)high-producing strain FIM-22-86 with abundant spore via protoplast heterologous fusion technology.The shake-flask fermentation titer of FK506 is 15.5%higher than that of the parent strain FIM-17-244.The fusion strain FIM-22-86 shows stable genetic characteristics,and the average fermentation titer reaches 1771μg·mL^(-1)after three batches of continuous fermentation in a 1 t fermenter.The fusion strain FIM-22-86 is expected to be used to reduce the industrial production cost of FK506.

关 键 词：链霉菌 他克莫司 发酵 原生质体融合 

分 类 号：TQ465.92[化学工程—制药化工]